# Medpace Holdings, Inc. – Consensus ‘buy’ rating and 3.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc-consensus-buy-rating-and-3-8-upside-potential/4121183956
- Published: 2025-01-17T15:16:40+00:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** with ticker code (MEDP) have now 10 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between $400.00 and $296.00 suggesting
an average Analsyt target price of $347.92. Now with the previous closing price 
of $335.23 and the analysts are correct then we can expect a percentage increase
in value of 3.8%. The 50 day MA is $340.82 while the 200 day moving average is $
369.96. The company has a market cap of 10.47B. The stock price is currently at:
$336.82 USD

 The potential market cap would be $10,865,294,933 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 29.49, revenue per share of $67.02
and a 14.31% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on: